ImmuCell Corp
NASDAQ:ICCC
EV/IC
Enterprise Value to IC
Enterprise Value to Invested Capital (EV/IC) ratio is a valuation multiple that measures the dollars in Enterprise Value for each dollar of capital invested by shareholders and lenders.
Market Cap | EV/IC | ||||
---|---|---|---|---|---|
US |
ImmuCell Corp
NASDAQ:ICCC
|
38m USD | 1.1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
287.2B USD | 3.6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
167.6B USD | 2.7 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.5B USD | 13.9 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.4B USD | 4.3 | ||
AU |
CSL Ltd
ASX:CSL
|
138.6B AUD | 3.1 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
84.1B USD | 1.5 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
50.3B USD | 5.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 19.3 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
33.3B USD | 1.6 | ||
KR |
Celltrion Inc
KRX:068270
|
40T KRW | 2.1 |
EV/IC Forward Multiples
Forward EV/IC multiple is a version of the EV/IC ratio that uses forecasted invested capital for the EV/IC calculation. 1-Year, 2-Years, and 3-Years forwards use invested capital forecasts for 1, 2, and 3 years ahead, respectively.